Los Angeles Capital Management
AMLX icon

Los Angeles Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Los Angeles Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.84K Hold
325
– – ﹤0.01% 2093
2026
Q1 		$4.52K Sell
325
-527
-62% -$7.41K ﹤0.01% 2155
2025
Q4 		$12K Buy
+852
New +$11.6K ﹤0.01% 2022
2025
Q3 		– Sell
-23,320
Closed -$149K – 1360
2025
Q2 		$149K Buy
+23,320
New +$113K ﹤0.01% 1229

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Los Angeles Capital Management's AMLX Position: Q2 2026 in Review

Los Angeles Capital Management held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 325 shares worth $5.84K. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Los Angeles Capital Management first reported a position in AMLX in Q2 2025 and has held it in 4 quarters since. The position peaked at $149K in Q2 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Los Angeles Capital Management held 325 shares of Amylyx Pharmaceuticals worth $5.84K as of Q2 2026.
  • Los Angeles Capital Management left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2093 holding.
  • Los Angeles Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Amylyx Pharmaceuticals position peaked at $149K in Q2 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.